Clinical trials: Thalidomide
Transfusion-dependent Thalassemia
Efficacy of Combination of Hdroxyurea and Thalidomide Over Hydroxyurea or Thalidomide in the Treatment of Transfusion Dependent Thalassemia in Children
The goal of this clinical trial is to find out the efficacy of combined Hydroxyurea and thalidomide transfusion dependent thalassemia patients.
- Trial name
- NCT06299670
- Testing
- Thalidomide, Hydroxy Urea, Combinations
- Where
- Bangladesh
- Volunteers
- 90 people
- Sponsor
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Multiple Myeloma
Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma
Multicentric study, open, single arm, designed to evaluate the efficacy(response rate and response duration) and security of a sequential scheme of treatment with Bortezomib in combination with Melfalan and Prednisone (V-MP)…
- Trial name
- TaCyDexVMP7 (NCT00652041)
- Testing
- Bortezomib, Thalidomide
- Where
- 5 sites in Spain
- Volunteers
- 40 people
- Sponsor
- PETHEMA Foundation
Multiple Myeloma
Escalating Doses of Thalidomide in Conjunction With Bortezomib and HIgh Dose Melphalan for BSCT
The primary objective of this study is to: Determine the maximum tolerated dose of thalidomide used in conjunction with dose-intense melphalan, bortezomib and autologous (syngeneic) HSC support in the salvage therapy of patients…
- Trial name
- Thal/Mel/Vel (NCT01242267)
- Testing
- Thalidomide+Melphalan +Bortezomib+stem cell transplant
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Hackensack Meridian Health
Extrapancreatic Neuroendocrine Tumor
A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Extrapancreatic Neuroendocrine Tumor
A Phase II Randomized,Controlled,Open Label,Multicentre Study to evaluate the efficacy and safety of Tegafur combined with Temozolomide versus Tegafur combined with Temozolomide and Thalidomide in subjects with Advanced…
- Trial name
- NCT03204032
- Testing
- Tegafur, Temozolomide, Thalidomide
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Chinese Academy of Medical Sciences
Melanoma
Thalidomide and Dacarbazine for Metastatic Melanoma
The purpose of this clinical trial is to assess the activity of thalidomide in combination with dacarbazine (DTIC) in patients with metastatic melanoma. Safety and toxicity of the two drugs will also be assessed.
- Trial name
- NCT00006200
- Testing
- thalidomide, dacarbazine
- Where
- United States
- Sponsor
- National Center for Research Resources (NCRR)
Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL)
Tumor Registry of Lymphatic Neoplasia
The purpose of this registry is to record information on therapy reality of malignant lymphatic systemic diseases by office-based haematologists in Germany.
- Conditions
- Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM)
- Trial name
- TLN-Registry (NCT00889798)
- Volunteers
- 3,795 people
- Sponsor
- iOMEDICO AG
Crohn's Disease
The Efficiency of MSC in Refractory Crohn's Disease
The investigators' preliminary study indicates that MSC is effective therapy in treating IBD. But the standard treatment is still lacking and the effect is not stable in IBD patients.
- Trial name
- NCT02532738
- Testing
- Routine Treatment of CD, MSC treatment 01, MSC treatment 02
- Volunteers
- 3 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Acute Myeloid Leukemia, Maintenance Treatment
The Maintenance Treatment of "ITIVA" in AML Patients
We apply for this clinical study to evaluate the efficacy of "combined recombinant human interference'- α- 1b, interleukin-2, and thalidomide" regimen in obtaining MRD positive AML patients in CR,as well as the efficacy of the…
- Conditions
- Acute Myeloid Leukemia, Maintenance Treatment, Minor Residue Disease, Interferon-α-1b
- Trial name
- NCT06256627
- Testing
- recombinant human interference'- α- 1b, interleukin-2, thalidomide, Venentoclax and Azacitidine
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Henan Cancer Hospital
Non-Hodgkin Lymphoma
Linperlisib Combination With Cyclophosphamide, Prednisone, and Thalidomide (CPT) in R/R NHL
This is a multicenter, open-label, non-randomized, multi-cohort study to evaluate the efficacy and safety of linperlisib combined with cyclophosphamide, prednisone, and thalidomide (CPT) regimen in the treatment of relapsed…
- Trial name
- NCT07195799
- Testing
- Linperlisib combined with CPT regimen
- Where
- China
- Volunteers
- 180 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Glioma
Phase II Trial of Peginterferon Alpha-2b and Thalidomide in Adults With Recurrent Gliomas
This study will examine the safety and effectiveness of peginterferon alpha-2b (PEG-Intron) alone and together with thalidomide in patients with gliomas (a type of brain tumor).
- Trial name
- NCT00047879
- Testing
- PEG-interferon alfa-2b, Thalidomide
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- National Cancer Institute (NCI)
Lupus or SLE, Interstitial Lung Disease
Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease
Recent data indicate that Telitacicept is beneficial for lupus nephritis. Our goal is to determine whether Telitacicept is an effective and safe treatment, compared to standard-of-care Cyclophosphamide, for subclinical and…
- Conditions
- Lupus or SLE, Interstitial Lung Disease, Systemic Lupus Erythematosus
- Trial name
- NCT07077486
- Testing
- Methylprednisolone (Corticosteroid), Immunosuppressant other than CYC, Telitacicept Freeze-dried powder Injection 80mg
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Tongji Hospital
Kidney Cancer
PEG-Interferon Alfa-2b, Sargramostim, and Thalidomide in Treating Patients With Metastatic Kidney Cancer
RATIONALE: PEG-interferon alfa-2b may interfere with the growth of tumor cells. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood.
- Trial name
- NCT00090870
- Testing
- PEG-interferon alfa-2b, GM-CSF, thalidomide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Medical University of South Carolina
Multiple Myeloma
DCEP in Combination With Thalidomide as Salvage Therapy for Post Transplantation Relapse
The purpose of this investigational trial is to find out how well patients respond and how long their response lasts when treated with a four day chemotherapy regimen involving dexamethasone, cytoxan, etoposide, and cisplatinum…
- Trial name
- NCT00083681
- Testing
- Thalidomide, Dexamethasone, Cytoxan
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- University of Arkansas
Advanced Nsclc
Study of Thalidomide in Treatment of Advanced Nsclc (Dream-003)
The study for innovative strategies is warranted in the treatment of advanced non-squamous NSCLC with epidermal growth factor receptor wild-type or unknown mutation status because the outcomes remain unsatisfactory for most…
- Trial name
- NCT03062800
- Testing
- Thalidomide, pemetrexed, cisplatin
- Where
- China
- Volunteers
- 232 people
- Sponsor
- Qilu Hospital of Shandong University
Multiple Myeloma, Peripheral Neuropathy
Serum Vitamin D Levels and Peripheral Neuropathy Among Multiple Myeloma Patients
This is a prospective study investigating the relationship between vitamin D and peripheral neuropathy (PN) among multiple myeloma (MM) patients treated with either bortezomib or thalidomide.
- Trial name
- NCT01697839
- Where
- 3 sites in United States
- Volunteers
- 110 people
- Sponsor
- Oncotherapeutics
Acquired Immunodeficiency Syndrome, HIV Infection
Home Treatment of HIV-Infected Patients With Interleukin-2 With or Without a Tumor Necrosis Factor Antagonist
Patients enrolled in NIH protocol 95-I-0133 at the Clinical Center may participate in an extension phase of this study in which the drug prednisone will be eliminated from the treatment regimen.
- Trial name
- NCT00001475
- Testing
- IL-2 plus Anti-TNF or Thalidomide
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Multiple Myeloma
UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy
This study has been designed to evaluate whether "anti-angiogenesis" therapy with thalidomide and whether additional chemotherapy after transplant will be beneficial.
- Trial name
- NCT00083551
- Testing
- Thalidomide, Ara-C, BCNU
- Where
- United States
- Volunteers
- 668 people
- Sponsor
- University of Arkansas
Arachnoiditis
Use of Thalidomide in Patients With Arachnoiditis
This pilot study will evaluate whether thalidomide decreases pain in patients with arachnoiditis.
- Trial name
- NCT00284505
- Testing
- thalidomide
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Washington University School of Medicine
Plasma Cell Myeloma, Renal Failure
Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure
This phase II trial studies how well daratumumab-based therapy works in treating patients with newly diagnosed multiple myeloma with kidney failure.
- Trial name
- NCT04352205
- Testing
- Bortezomib, Daratumumab, Dexamethasone
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Emory University
Multiple Myeloma
A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma
The purpose of this study is to determine if Thalidomide + Dexamethasone or DOXIL (doxorubicin HCl liposome injection) + Thalidomide + Dexamethasone is more effective in treating newly diagnosed patients with multiple myeloma.
- Trial name
- NCT00097981
- Testing
- Thalidomide, Dexamethasone, DOXIL
- Where
- 58 sites in United States
- Volunteers
- 225 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.